CHRISTINE LECOUNT: Open Payments
NPI 1902505696 · RALEIGH, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$933 in 41 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $226 · 2025 $933
Food & beverage: $933
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $235 |
| ABBVIE INC. | 11 | $190 |
| Neurocrine BioSciences, Inc. | 10 | $149 |
| Alkermes, Inc. | 5 | $109 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Tris Pharma Inc | 3 | $52 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
Products named: INVEGA SUSTENNA, VRAYLAR, INGREZZA, ARISTADA, CAPLYTA, Dyanavel XR, COBENFY, HETLIOZ.
Industry payments across NC — which companies pay providers there.
